Hub : Traits :

Type 2 Diabetes (T2D) (2018)

350 significantly associated models · 98 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	39182130	40737589	6	1	1.7e-11	3.3e-10	7.9e-03	82	RP11-69E11.4
2	1	119761038	120687115	2	1	4.0e-08	2.8e-08	1.0e+00	100	RP5-1042I8.7
3	1	213759712	215206914	1	1	3.0e-09	2.0e-12	2.9e-05	65	SMYD2
4	1	235684842	237144310	1	1	1.6e-07	1.6e-07	1.0e+00	100	ERO1LB
5	2	26655745	28607344	8	1	4.4e-15	3.4e-15	1.0e+00	100	FNDC4
6	2	42753863	44157441	2	1	3.9e-15	1.0e-16	6.8e-03	89	AC010883.5
7	2	164657815	166170073	1	1	2.2e-07	5.8e-15	9.9e-10	39	GRB14
8	3	22998569	23879862	1	1	3.1e-09	1.1e-11	6.6e-04	75	UBE2E2
9	3	49030828	50800146	7	1	9.4e-10	2.4e-09	4.1e-02	88	RBM6
10	3	137385728	138819532	1	1	3.2e-08	9.7e-08	2.8e-01	96	MRAS
11	3	185112300	185786406	1	1	5.5e-24	5.9e-28	2.0e-05	85	IGF2BP2
12	4	5575751	7002344	1	1	5.3e-17	9.6e-19	6.3e-05	80	WFS1
13	5	101726770	103143067	1	1	1.9e-07	8.7e-07	3.5e-01	96	GIN1
14	6	6582123	8009760	1	1	7.7e-13	2.2e-07	3.0e-03	67	SSR1
15	6	19703618	21930988	2	2	4.6e-11	1.0e-31	1.5e-20	37	CDKAL1 E2F3
16	7	6502367	7988091	1	1	9.3e-08	6.9e-07	8.7e-01	100	C1GALT1
17	7	27623776	28468319	1	1	8.3e-16	4.0e-18	3.0e-04	83	JAZF1
18	7	73624615	74494207	1	1	2.0e-07	4.3e-07	1.0e+00	100	PMS2P5
19	7	102334106	103489729	1	1	1.1e-08	1.1e-06	9.9e-01	100	NAPEPLD
20	7	156687822	157308348	1	1	2.9e-08	7.5e-08	1.0e+00	100	UBE3C
21	8	40811597	42450441	1	2	1.4e-14	1.7e-15	1.0e+00	100	ANK1
22	8	95199215	96607028	1	1	1.5e-07	2.7e-09	5.3e-03	78	CCNE2
23	8	145018354	146293414	3	2	1.6e-07	3.3e-07	4.2e-01	98	KIFC2 ZNF251
24	10	11477584	13569805	4	1	2.3e-13	6.6e-14	1.0e+00	100	CAMK1D
25	10	80443273	81901722	1	1	5.4e-12	3.7e-15	1.6e-05	70	ZCCHC24
26	10	92860281	95151622	6	1	4.4e-28	8.0e-27	1.8e-03	92	EIF2S2P3
27	10	101291593	102725979	2	1	1.5e-08	5.8e-08	7.2e-01	100	RP11-316M21.6
28	10	113511441	115622375	2	1	2.0e-59	1.7e-204	1.4e-155	24	TCF7L2
29	11	2213166	3597515	1	1	1.2e-15	3.0e-19	2.5e-14	28	CDKN1C
30	11	16691743	18106069	4	1	1.5e-11	1.3e-12	4.7e-03	84	RP1-239B22.5
31	11	64615450	66333072	4	2	6.8e-10	1.7e-08	4.4e-01	98	CTSW SSSCA1-AS1
32	11	71339667	73198494	3	2	3.0e-08	2.6e-16	6.7e-07	63	ARAP1 CLPB
33	12	122942185	124424636	1	1	3.4e-08	1.0e-04	7.3e-01	99	MPHOSPH9
34	15	41119185	42528982	1	1	1.9e-07	2.6e-07	1.0e+00	100	RPAP1
35	15	74951357	78474476	7	2	1.7e-09	1.9e-11	1.3e-03	77	HMG20A SNUPN
36	15	89680384	91135411	3	1	4.1e-10	3.7e-09	7.0e-01	100	AP3S2
37	16	52772129	54235440	2	1	3.0e-09	3.1e-29	3.5e-29	0	RBL2
38	16	69354963	69975360	1	1	3.7e-08	6.2e-10	1.6e-03	74	NFAT5
39	16	74635632	76159151	1	1	7.0e-08	3.4e-12	3.9e-06	56	CFDP1
40	17	3208350	4863410	2	1	1.5e-07	1.4e-08	2.7e-02	85	ANKFY1
41	17	60858059	62259376	1	1	2.0e-07	1.7e-07	1.0e+00	100	ACE
42	19	12829697	13325733	1	1	9.1e-08	8.8e-07	9.0e-01	100	DAND5
43	19	45313715	46846078	3	2	9.5e-10	5.7e-13	4.9e-04	77	PPM1N SNRPD2
44	20	31701333	33116483	1	1	3.9e-09	8.1e-09	1.0e+00	100	CHMP4B

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Diabetes diagnosed by doctor	19.61	48	23	51.1	0.99	2.5e-45	AC010883.5 ACE ANK1 AP3S2 ARAP1 C1GALT1 CAMK1D CCNE2 CDKAL1 CDKN1C CFDP1 CHMP4B CLPB CTSW DAND5 E2F3 EIF2S2P3 ERO1LB FNDC4 GIN1 HMG20A IGF2BP2 JAZF1 KIFC2 MPHOSPH9 MRAS NAPEPLD NFAT5 PMS2P5 PPM1N RBL2 RBM6 RP11-316M21.6 RP11-69E11.4 RP1-239B22.5 RP5-1042I8.7 RPAP1 SMYD2 SNRPD2 SNUPN SSR1 SSSCA1-AS1 TCF7L2 UBE2E2 UBE3C WFS1 ZCCHC24 ZNF251
Diabetes (self-reported)	18.49	43	18	40.0	0.99	7.1e-38	AC010883.5 ANK1 AP3S2 ARAP1 C1GALT1 CAMK1D CCNE2 CDKN1C CFDP1 CHMP4B CLPB DAND5 E2F3 EIF2S2P3 ERO1LB FNDC4 HMG20A IGF2BP2 JAZF1 KIFC2 MPHOSPH9 MRAS NAPEPLD NFAT5 PMS2P5 PPM1N RBL2 RBM6 RP11-69E11.4 RP1-239B22.5 RP5-1042I8.7 RPAP1 SMYD2 SNRPD2 SNUPN SSR1 SSSCA1-AS1 TCF7L2 UBE2E2 UBE3C WFS1 ZCCHC24 ZNF251
Medication: Metformin	14.68	27	11	24.4	0.99	1.9e-23	AC010883.5 ANK1 AP3S2 CAMK1D CFDP1 DAND5 EIF2S2P3 ERO1LB FNDC4 IGF2BP2 JAZF1 MPHOSPH9 MRAS PMS2P5 PPM1N RBL2 RBM6 RP11-69E11.4 RP1-239B22.5 RPAP1 SNUPN SSSCA1-AS1 TCF7L2 UBE2E2 UBE3C WFS1 ZCCHC24
Type 2 Diabetes (T2D) (2012)	9.45	7	5	11.1	0.97	2.4e-04	ANK1 EIF2S2P3 IGF2BP2 JAZF1 SSR1 TCF7L2 WFS1
Diabetes (father)	9.44	13	4	8.9	0.99	1.2e-11	AC010883.5 ANK1 AP3S2 CDKAL1 E2F3 EIF2S2P3 FNDC4 GIN1 IGF2BP2 JAZF1 SNRPD2 SSR1 TCF7L2
Diabetes (mother)	9.35	15	5	11.1	0.98	2.0e-10	AC010883.5 ANK1 ARAP1 CAMK1D CDKAL1 DAND5 EIF2S2P3 FNDC4 IGF2BP2 SNRPD2 SSSCA1-AS1 TCF7L2 UBE2E2 UBE3C WFS1
Triglycerides	9.34	2	2	4.4	0.00	1.0e+00	FNDC4 GRB14
Medication: Gliclazide	7.90	8	2	4.4	0.99	2.0e-06	CTSW IGF2BP2 JAZF1 MRAS TCF7L2 UBE2E2 UBE3C WFS1
Illnesses of siblings: Diabetes	5.97	7	3	6.7	0.97	3.1e-04	CAMK1D EIF2S2P3 IGF2BP2 PMS2P5 SNRPD2 TCF7L2 WFS1
Fasting Glucose	5.13	3	1	2.2	0.00	1.0e+00	ARAP1 CLPB FNDC4
Eye problems/disorders: Diabetes related eye disease	4.26	2	0	0.0	0.00	1.0e+00	IGF2BP2 TCF7L2
Medication for cholesterol, blood pressure or diabetes	4.07	10	0	0.0	-0.74	1.4e-02	ACE C1GALT1 CAMK1D CHMP4B CTSW FNDC4 IGF2BP2 MRAS PPM1N RBM6
Medication: Cholesterol lowering	3.98	6	1	2.2	0.18	7.3e-01	C1GALT1 CFDP1 FNDC4 IGF2BP2 MRAS TCF7L2
High cholesterol (Self-reported)	3.77	2	1	2.2	0.00	1.0e+00	FNDC4 MPHOSPH9
Waist Hip Ratio (WHR)	3.76	18	13	28.9	0.76	2.6e-04	AC010883.5 ANKFY1 CDKAL1 CTSW EIF2S2P3 GIN1 GRB14 IGF2BP2 JAZF1 MPHOSPH9 MRAS RBL2 RP1-239B22.5 RPAP1 SNRPD2 SNUPN TCF7L2 ZCCHC24
Cardiovascular Disease	3.63	14	7	15.6	0.69	6.7e-03	ACE C1GALT1 CCNE2 CFDP1 CTSW FNDC4 IGF2BP2 KIFC2 MPHOSPH9 MRAS NFAT5 PMS2P5 RP1-239B22.5 ZNF251
Medication: Simvastatin	3.54	3	1	2.2	0.00	1.0e+00	CTSW FNDC4 TCF7L2
Cholesterol lowering medication	3.46	3	1	2.2	0.00	1.0e+00	FNDC4 TCF7L2 UBE3C
Blood Platelet Count	3.30	18	15	33.3	-0.31	2.2e-01	AC010883.5 ANKFY1 AP3S2 CCNE2 CDKAL1 CDKN1C CFDP1 CTSW EIF2S2P3 FNDC4 IGF2BP2 MPHOSPH9 PPM1N RP11-69E11.4 RP1-239B22.5 SNRPD2 SNUPN SSSCA1-AS1
Alcohol intake frequency.	3.27	4	2	4.4	-0.05	9.5e-01	FNDC4 NFAT5 PMS2P5 RBM6
Lung FEV1/FVC ratio	3.17	12	9	20.0	-0.32	3.1e-01	AC010883.5 ANKFY1 C1GALT1 CAMK1D CFDP1 CLPB HMG20A IGF2BP2 PPM1N RP11-69E11.4 RPAP1 SNRPD2
Gout (self-reported)	3.17	2	1	2.2	0.00	1.0e+00	FNDC4 NFAT5
Birth weight	3.15	7	2	4.4	-0.49	2.1e-01	ANK1 CCNE2 CDKAL1 CFDP1 E2F3 EIF2S2P3 SMYD2
Long-standing illness, disability or infirmity	3.12	5	0	0.0	0.96	9.9e-03	IGF2BP2 MRAS NFAT5 PMS2P5 RP11-69E11.4
Number of treatments/medications taken	3.10	5	1	2.2	0.55	3.4e-01	C1GALT1 CTSW FNDC4 MRAS RBM6
Vascular/heart problems diagnosed by doctor	2.98	8	4	8.9	-0.98	2.2e-05	ACE C1GALT1 CCNE2 CTSW MRAS NFAT5 PMS2P5 PPM1N
Medication: Ramipril	2.97	3	0	0.0	0.00	1.0e+00	ANKFY1 CTSW MRAS
Pulse rate, automated reading	2.97	8	6	13.3	0.36	3.8e-01	FNDC4 JAZF1 NFAT5 RBL2 RBM6 RP11-69E11.4 SSSCA1-AS1 WFS1
Hypertension (Self-reported)	2.86	7	3	6.7	0.98	1.4e-04	ACE C1GALT1 CCNE2 CTSW MRAS PMS2P5 RP1-239B22.5
High blood pressure	2.84	8	4	8.9	0.98	2.4e-05	ACE C1GALT1 CCNE2 CTSW MRAS NFAT5 PMS2P5 RP1-239B22.5
Number of self-reported non-cancer illnesses	2.84	4	1	2.2	0.36	6.4e-01	FNDC4 MPHOSPH9 NFAT5 PMS2P5
Medication: Allopurinol	2.82	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Atorvastatin	2.80	2	1	2.2	0.00	1.0e+00	FNDC4 TCF7L2
Medication: Blood pressure	2.77	4	0	0.0	0.99	9.3e-03	ACE C1GALT1 CAMK1D CTSW
Body mass index (BMI)	2.68	9	4	8.9	0.20	6.0e-01	CTSW FNDC4 GRB14 HMG20A JAZF1 NFAT5 PMS2P5 RBM6 TCF7L2
Overall health rating	2.67	4	2	4.4	0.98	1.6e-02	CTSW PMS2P5 RBL2 RBM6
Leg fat percentage (right)	2.65	9	4	8.9	0.22	5.8e-01	ANKFY1 CTSW GRB14 HMG20A NFAT5 RBM6 SNUPN TCF7L2 ZCCHC24
Medication for cholesterol	2.62	1	1	2.2	0.00	1.0e+00	FNDC4
Leg fat percentage (left)	2.62	9	4	8.9	0.22	5.7e-01	CTSW GRB14 HMG20A MPHOSPH9 NFAT5 RBM6 SNUPN TCF7L2 ZCCHC24
BMI	2.57	16	7	15.6	0.30	2.5e-01	ANKFY1 CTSW DAND5 FNDC4 GIN1 GRB14 HMG20A JAZF1 NFAT5 PMS2P5 PPM1N RBM6 RP11-69E11.4 RP1-239B22.5 TCF7L2 ZCCHC24
Impedance of arm (left)	2.56	11	8	17.8	-0.25	4.7e-01	CTSW DAND5 E2F3 FNDC4 GRB14 HMG20A JAZF1 RBM6 RP1-239B22.5 SSSCA1-AS1 TCF7L2
Arm fat percentage (left)	2.49	6	4	8.9	-0.01	9.8e-01	CTSW GRB14 NFAT5 PMS2P5 RBM6 TCF7L2
HDL Cholesterol	2.48	4	2	4.4	-0.99	1.2e-02	CTSW GRB14 RBM6 RP11-69E11.4
Medication: Blood pressure	2.47	4	1	2.2	0.98	1.8e-02	C1GALT1 CTSW MRAS RP1-239B22.5
Impedance of whole body	2.47	10	6	13.3	-0.27	4.5e-01	AC010883.5 CTSW E2F3 FNDC4 GRB14 HMG20A JAZF1 RBL2 RBM6 RP1-239B22.5
Alcohol intake versus 10 years previously	2.46	3	2	4.4	0.00	1.0e+00	FNDC4 RBM6 RP11-69E11.4
Leg fat mass (right)	2.45	9	5	11.1	0.26	5.0e-01	ANKFY1 CTSW FNDC4 GRB14 HMG20A NAPEPLD NFAT5 RBM6 TCF7L2
Leg fat mass (left)	2.44	9	5	11.1	0.27	4.7e-01	ANKFY1 CTSW FNDC4 GRB14 HMG20A NFAT5 RBM6 TCF7L2 ZCCHC24
Medication: Aspirin	2.43	1	0	0.0	0.00	1.0e+00	IGF2BP2
Age when periods started (menarche)	2.41	6	3	6.7	-0.74	9.3e-02	CTSW DAND5 NFAT5 PMS2P5 RP11-316M21.6 SSSCA1-AS1
Impedance of arm (right)	2.41	11	6	13.3	-0.24	4.9e-01	CTSW DAND5 E2F3 FNDC4 GRB14 HMG20A JAZF1 RBM6 RP1-239B22.5 SSSCA1-AS1 TCF7L2
Arm fat percentage (right)	2.41	5	4	8.9	-0.02	9.7e-01	CTSW GRB14 NFAT5 RBM6 TCF7L2
Body fat percentage	2.41	6	3	6.7	-0.06	9.2e-01	CTSW GRB14 NFAT5 RBM6 TCF7L2 ZCCHC24
Crohns Disease (2017)	2.39	5	3	6.7	-0.68	2.1e-01	AC010883.5 FNDC4 JAZF1 PMS2P5 RBM6
Breast Cancer	2.39	5	1	2.2	-0.73	1.6e-01	CDKAL1 DAND5 PMS2P5 SNUPN TCF7L2
Fluid intelligence score	2.37	5	1	2.2	-0.04	9.4e-01	KIFC2 NFAT5 RBL2 RBM6 RP1-239B22.5
Impedance of leg (left)	2.36	10	7	15.6	-0.34	3.3e-01	AC010883.5 CTSW FNDC4 GIN1 JAZF1 NFAT5 RBL2 RBM6 RP11-69E11.4 RP1-239B22.5
Medication: Aspirin	2.34	1	0	0.0	0.00	1.0e+00	IGF2BP2
Taking other prescription medications	2.33	3	1	2.2	0.00	1.0e+00	MRAS PMS2P5 RBM6
Waist circumference	2.33	8	4	8.9	0.50	2.0e-01	ANKFY1 CTSW FNDC4 NFAT5 RBM6 RP11-69E11.4 TCF7L2 ZCCHC24
Verbal and Numeric Reasoning (VNR)	2.32	5	2	4.4	-0.15	8.1e-01	GIN1 KIFC2 NFAT5 RBL2 RBM6
Systolic Blood Pressure	2.31	14	5	11.1	0.78	1.0e-03	C1GALT1 CAMK1D CCNE2 CFDP1 CTSW FNDC4 GRB14 JAZF1 MRAS NFAT5 RBM6 RP1-239B22.5 SSSCA1-AS1 TCF7L2
Intelligence (Savage-Jansen 2018)	2.28	4	3	6.7	-0.67	3.3e-01	KIFC2 RBL2 RBM6 RP11-316M21.6
Arm fat mass (right)	2.26	7	4	8.9	0.23	6.2e-01	CTSW FNDC4 GRB14 NFAT5 RBM6 RP11-69E11.4 TCF7L2
Impedance of leg (right)	2.25	11	7	15.6	-0.35	2.9e-01	AC010883.5 CTSW FNDC4 GIN1 JAZF1 NFAT5 PMS2P5 RBL2 RBM6 RP11-69E11.4 RP1-239B22.5
Lung FVC	2.23	12	7	15.6	-0.89	1.2e-04	C1GALT1 CAMK1D CHMP4B CLPB IGF2BP2 JAZF1 KIFC2 MRAS NFAT5 RBM6 SNUPN ZCCHC24
Arm fat mass (left)	2.23	7	4	8.9	0.23	6.1e-01	CTSW FNDC4 GRB14 NFAT5 RBM6 RP11-69E11.4 TCF7L2
Whole body fat mass	2.21	6	4	8.9	0.09	8.6e-01	ANKFY1 CTSW GRB14 NFAT5 RBM6 TCF7L2
Coronary Artery Disease (CAD)	2.18	2	0	0.0	0.00	1.0e+00	CFDP1 MRAS
Trunk fat percentage	2.16	5	3	6.7	0.38	5.3e-01	CTSW GRB14 NFAT5 RBM6 ZCCHC24
Forced expiratory volume in 1-second (FEV1), Best measure	2.10	7	2	4.4	-0.97	2.5e-04	C1GALT1 CAMK1D IGF2BP2 MRAS NFAT5 SNUPN ZCCHC24
Age at last live birth	2.10	2	1	2.2	0.00	1.0e+00	EIF2S2P3 RBM6
Arm predicted mass (left)	2.10	9	3	6.7	0.50	1.7e-01	CTSW FNDC4 JAZF1 MPHOSPH9 NAPEPLD RBL2 RBM6 SNUPN SSR1
Arm fat-free mass (right)	2.09	8	4	8.9	0.48	2.3e-01	CTSW FNDC4 JAZF1 MPHOSPH9 RBL2 RBM6 SNUPN SSR1
Trunk fat-free mass	2.07	9	6	13.3	0.38	3.1e-01	FNDC4 JAZF1 MPHOSPH9 NAPEPLD RBL2 RBM6 RP11-69E11.4 SNUPN SSR1
Trunk predicted mass	2.07	8	6	13.3	0.37	3.7e-01	FNDC4 JAZF1 MPHOSPH9 RBL2 RBM6 RP11-69E11.4 SNUPN SSR1
Arm fat-free mass (left)	2.07	9	3	6.7	0.51	1.6e-01	CTSW FNDC4 JAZF1 MPHOSPH9 NAPEPLD RBL2 RBM6 SNUPN SSR1
Forced expiratory volume in 1-second (FEV1)	2.06	7	2	4.4	-0.98	9.9e-05	C1GALT1 CAMK1D IGF2BP2 NFAT5 SNRPD2 SNUPN ZCCHC24
Age at First Birth	2.05	2	1	2.2	0.00	1.0e+00	KIFC2 RBM6
Peak expiratory flow (PEF)	2.05	5	2	4.4	-0.99	9.2e-04	AC010883.5 C1GALT1 CAMK1D IGF2BP2 NFAT5
Arm predicted mass (right)	2.05	8	3	6.7	0.58	1.3e-01	CTSW FNDC4 JAZF1 NAPEPLD RBL2 RBM6 SNUPN SSR1
Irritable Bowel Disease (IBD)	2.04	4	3	6.7	-1.00	3.2e-03	AC010883.5 FNDC4 PMS2P5 RBM6
Blood Red Count	2.04	14	8	17.8	0.75	2.1e-03	CCNE2 DAND5 FNDC4 GIN1 GRB14 HMG20A IGF2BP2 KIFC2 NFAT5 PPM1N RBM6 RPAP1 SNRPD2 SNUPN
Diastolic blood pressure, automated reading	2.03	6	5	11.1	1.00	3.3e-05	ANKFY1 C1GALT1 CTSW MPHOSPH9 PMS2P5 RBM6
Height	2.01	19	14	31.1	-0.05	8.3e-01	AC010883.5 ACE AP3S2 CFDP1 CTSW DAND5 FNDC4 GIN1 HMG20A JAZF1 MPHOSPH9 MRAS NFAT5 RBL2 RP11-316M21.6 RP1-239B22.5 SNUPN SSR1 UBE2E2
Crohns Disease (2012)	2.00	1	0	0.0	0.00	1.0e+00	RBM6
Trunk fat mass	1.99	7	3	6.7	0.19	6.9e-01	ANKFY1 CTSW GRB14 NFAT5 RBM6 RP11-69E11.4 TCF7L2
Sitting height	1.98	13	8	17.8	-0.22	4.6e-01	FNDC4 JAZF1 MPHOSPH9 MRAS NFAT5 RBL2 RP11-69E11.4 SNRPD2 SNUPN SSR1 UBE2E2 UBE3C ZCCHC24
Whole body water mass	1.98	10	4	8.9	0.44	2.0e-01	CTSW FNDC4 JAZF1 MPHOSPH9 NAPEPLD RBL2 RBM6 RP11-69E11.4 SNUPN SSR1
Standing height	1.97	12	9	20.0	0.12	7.2e-01	DAND5 FNDC4 GIN1 JAZF1 MPHOSPH9 NFAT5 RBL2 RP11-316M21.6 RP1-239B22.5 SNRPD2 SNUPN SSR1
Comparative height size at age 10	1.96	8	6	13.3	0.04	9.2e-01	AC010883.5 FNDC4 JAZF1 MPHOSPH9 RBL2 RP1-239B22.5 SNRPD2 UBE2E2
Hip circumference	1.95	7	5	11.1	-0.14	7.6e-01	FNDC4 GRB14 NFAT5 RBL2 RBM6 RP11-69E11.4 TCF7L2
Whole body fat-free mass	1.95	9	4	8.9	0.41	2.7e-01	FNDC4 JAZF1 MPHOSPH9 NAPEPLD RBL2 RBM6 RP11-69E11.4 SNUPN SSR1
Weight	1.94	10	3	6.7	0.30	4.0e-01	ANKFY1 CTSW FNDC4 GRB14 NAPEPLD NFAT5 RBL2 RBM6 RP11-69E11.4 TCF7L2
Mouth/teeth dental problems: Dentures	1.93	3	0	0.0	0.00	1.0e+00	CLPB PMS2P5 RBM6
Forced vital capacity (FVC), Best measure	1.93	8	3	6.7	-0.76	2.8e-02	CAMK1D HMG20A MRAS NFAT5 SNRPD2 SNUPN SSR1 ZCCHC24
Forced vital capacity (FVC)	1.92	9	3	6.7	-0.78	1.3e-02	CAMK1D HMG20A MRAS NFAT5 SMYD2 SNRPD2 SNUPN SSR1 ZCCHC24
Illnesses of mother	1.92	1	0	0.0	0.00	1.0e+00	IGF2BP2
Basal metabolic rate	1.91	10	3	6.7	0.50	1.4e-01	CTSW FNDC4 JAZF1 MPHOSPH9 NAPEPLD RBL2 RBM6 RP11-69E11.4 SNUPN SSR1
Chronotype (morning person)	1.89	3	2	4.4	0.00	1.0e+00	NAPEPLD NFAT5 PPM1N
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.86	6	1	2.2	-0.74	9.4e-02	ANKFY1 CAMK1D IGF2BP2 JAZF1 MRAS NFAT5
Pulse rate	1.85	2	1	2.2	0.00	1.0e+00	FNDC4 RBL2
Qualifications: College or University degree	1.85	4	1	2.2	-0.63	3.7e-01	KIFC2 MPHOSPH9 RBL2 RBM6
Qualifications: A levels/AS levels or equivalent	1.81	2	1	2.2	0.00	1.0e+00	MPHOSPH9 RBM6
Age at first live birth	1.81	1	1	2.2	0.00	1.0e+00	RBM6
Leg fat-free mass (left)	1.80	7	4	8.9	0.39	3.8e-01	CTSW FNDC4 MPHOSPH9 RBL2 RBM6 RP11-69E11.4 SNUPN
Leg predicted mass (left)	1.80	7	4	8.9	0.39	3.8e-01	CTSW FNDC4 MPHOSPH9 RBL2 RBM6 RP11-69E11.4 SNUPN
Systolic blood pressure, automated reading	1.79	6	3	6.7	1.00	1.5e-06	CAMK1D CFDP1 CTSW NFAT5 PMS2P5 RP1-239B22.5
Leg fat-free mass (right)	1.74	7	4	8.9	0.37	4.2e-01	CTSW FNDC4 MPHOSPH9 RBL2 RBM6 RP11-69E11.4 SNUPN
Wheeze or whistling in the chest in last year	1.73	1	1	2.2	0.00	1.0e+00	RBM6
Leg predicted mass (right)	1.73	7	4	8.9	0.37	4.2e-01	CTSW FNDC4 MPHOSPH9 RBL2 RBM6 RP11-69E11.4 SNUPN
Mother's age at death	1.71	1	0	0.0	0.00	1.0e+00	SNUPN
Qualifications: CSEs or equivalent	1.70	1	0	0.0	0.00	1.0e+00	RBM6
Heel T-Score	1.68	14	6	13.3	0.52	5.7e-02	AC010883.5 ANKFY1 CTSW IGF2BP2 MPHOSPH9 MRAS PMS2P5 RBM6 RP11-316M21.6 RP11-69E11.4 SMYD2 SNRPD2 SSR1 SSSCA1-AS1
Qualifications: None of the above	1.67	3	2	4.4	0.00	1.0e+00	MPHOSPH9 RBL2 RBM6
Headache pain in last month	1.67	1	0	0.0	0.00	1.0e+00	RP11-316M21.6
High blood pressure (mother)	1.64	1	0	0.0	0.00	1.0e+00	MRAS
Father's age at death	1.64	1	0	0.0	0.00	1.0e+00	MPHOSPH9
Smoking status: Previous	1.63	3	0	0.0	0.00	1.0e+00	CTSW DAND5 KIFC2
Mouth/teeth dental problems	1.60	2	0	0.0	0.00	1.0e+00	PMS2P5 RP1-239B22.5
Forced expiratory volume in 1-second (FEV1), predicted	1.60	1	1	2.2	0.00	1.0e+00	JAZF1
Birth weight of first child	1.59	1	0	0.0	0.00	1.0e+00	SSR1
Fed-up feelings	1.58	3	0	0.0	0.00	1.0e+00	AC010883.5 MPHOSPH9 RBM6
Number of full brothers	1.56	1	0	0.0	0.00	1.0e+00	HMG20A
Qualifications: NVQ or HND or HNC or equivalent	1.56	1	0	0.0	0.00	1.0e+00	RBM6
Knee pain experienced in last month	1.56	1	0	0.0	0.00	1.0e+00	ZCCHC24
Ever highly irritable/argumentative for 2 days	1.55	2	0	0.0	0.00	1.0e+00	RBM6 SNUPN
Illnesses of father: Heart disease	1.55	1	0	0.0	0.00	1.0e+00	ZCCHC24
Number of live births	1.54	2	0	0.0	0.00	1.0e+00	KIFC2 RBM6
Miserableness	1.54	2	1	2.2	0.00	1.0e+00	MPHOSPH9 RBM6
Alzheimer’s Disease (including proxy)	1.53	1	0	0.0	0.00	1.0e+00	ACE
Past tobacco smoking	1.53	1	0	0.0	0.00	1.0e+00	KIFC2
Hair/balding pattern: Pattern 4	1.53	2	1	2.2	0.00	1.0e+00	AC010883.5 CDKAL1
Heel bone mineral density (BMD) T-score, automated (left)	1.49	3	1	2.2	0.00	1.0e+00	CTSW RBM6 SSSCA1-AS1
Financial situation satisfaction	1.48	1	0	0.0	0.00	1.0e+00	RBM6
Ulcerative Colitis (UC)	1.47	2	0	0.0	0.00	1.0e+00	CFDP1 RBM6
Ulcerative Colitis	1.46	2	0	0.0	0.00	1.0e+00	CFDP1 RBM6
Allergy or Eczema	1.46	4	0	0.0	-0.57	4.3e-01	AC010883.5 CFDP1 FNDC4 JAZF1
Frequency of tenseness / restlessness in last 2 weeks	1.46	1	0	0.0	0.00	1.0e+00	MPHOSPH9
Heel bone mineral density (BMD) T-score, automated (right)	1.45	3	0	0.0	0.00	1.0e+00	CTSW RBM6 SSSCA1-AS1
Frequency of tiredness / lethargy in last 2 weeks	1.43	1	0	0.0	0.00	1.0e+00	MPHOSPH9
Mood swings	1.43	1	1	2.2	0.00	1.0e+00	RBM6
Blood White Count	1.42	5	3	6.7	0.17	7.9e-01	FNDC4 GIN1 RBM6 RP11-69E11.4 SNUPN
Relative age of first facial hair	1.42	1	1	2.2	0.00	1.0e+00	FNDC4
Ever had bowel cancer screening	1.42	1	0	0.0	0.00	1.0e+00	RBM6
Age started oral contraceptive pill	1.42	1	0	0.0	0.00	1.0e+00	RBM6
Alcohol drinker status: Previous	1.42	1	0	0.0	0.00	1.0e+00	DAND5
Pain experienced in last month	1.40	1	0	0.0	0.00	1.0e+00	RBM6
Schizophrenia vs Biploar Disorder	1.39	1	0	0.0	0.00	1.0e+00	FNDC4
Hayfever, allergic rhinitis or eczema	1.38	1	0	0.0	0.00	1.0e+00	AC010883.5
Depressed Affect (Nagel 2018)	1.37	3	0	0.0	0.00	1.0e+00	AC010883.5 MPHOSPH9 RBM6
Irritability	1.36	2	0	0.0	0.00	1.0e+00	AC010883.5 ANKFY1
Hand grip strength (left)	1.35	1	1	2.2	0.00	1.0e+00	NFAT5
Serious illness, injury or assault to yourself	1.35	1	0	0.0	0.00	1.0e+00	NFAT5
Ever smoked	1.35	1	0	0.0	0.00	1.0e+00	KIFC2
Medication: Co-codamol	1.34	1	0	0.0	0.00	1.0e+00	RBM6
Tanning	1.33	5	4	8.9	0.86	6.4e-02	CHMP4B FNDC4 JAZF1 RP11-316M21.6 RP5-1042I8.7
Hand grip strength (right)	1.33	2	0	0.0	0.00	1.0e+00	NFAT5 SNUPN
Chronic bronchitis/emphysema (mother)	1.33	1	0	0.0	0.00	1.0e+00	RBM6
Pack years of smoking	1.32	1	0	0.0	0.00	1.0e+00	PMS2P5
Bipolar Disorder (2018)	1.31	1	0	0.0	0.00	1.0e+00	FNDC4
Angina (self-reported)	1.31	1	0	0.0	0.00	1.0e+00	CFDP1
Pack years adult smoking proportion	1.30	1	0	0.0	0.00	1.0e+00	PMS2P5
Qualifications: nursing, teaching	1.29	1	0	0.0	0.00	1.0e+00	RBM6
Exposure to tobacco smoke outside home	1.28	1	0	0.0	0.00	1.0e+00	RBM6
Neuroticism score	1.27	3	0	0.0	0.00	1.0e+00	AC010883.5 MPHOSPH9 RBM6
Health satisfaction	1.27	1	0	0.0	0.00	1.0e+00	RBM6
Blood Eosinophil Count	1.26	8	6	13.3	0.16	7.0e-01	AC010883.5 CCNE2 EIF2S2P3 JAZF1 MPHOSPH9 NFAT5 RBM6 SSSCA1-AS1
Asthma	1.25	2	0	0.0	0.00	1.0e+00	EIF2S2P3 JAZF1
Medication: Ventolin 100micrograms inhaler	1.25	1	0	0.0	0.00	1.0e+00	RBM6
Leg pain on walking	1.24	1	0	0.0	0.00	1.0e+00	RBM6
Average weekly beer plus cider intake	1.24	1	1	2.2	0.00	1.0e+00	RBM6
Respiratory disease	1.22	3	0	0.0	0.00	1.0e+00	EIF2S2P3 JAZF1 RBM6
Allergy	1.22	2	0	0.0	0.00	1.0e+00	AC010883.5 JAZF1
Maternal smoking around birth	1.21	1	0	0.0	0.00	1.0e+00	RBM6
Asthma (self-reported)	1.21	1	0	0.0	0.00	1.0e+00	EIF2S2P3
Comparative body size at age 10	1.20	1	0	0.0	0.00	1.0e+00	MRAS
Rheumatoid Arthritis	1.19	1	0	0.0	0.00	1.0e+00	GIN1
Medication: Seretide 50 evohaler	1.19	1	0	0.0	0.00	1.0e+00	RBM6
Neuroticism (Nagel 2018)	1.18	1	0	0.0	0.00	1.0e+00	AC010883.5
Worrier / anxious feelings	1.16	1	0	0.0	0.00	1.0e+00	GIN1
Relative age voice broke	1.14	1	0	0.0	0.00	1.0e+00	NFAT5
Supplements: Vitamin C	1.14	1	0	0.0	0.00	1.0e+00	NFAT5
Qualifications: O levels/GCSEs or equivalent	1.13	1	0	0.0	0.00	1.0e+00	MPHOSPH9
Neuroticism	1.08	1	0	0.0	0.00	1.0e+00	RBM6
Hypothyroidism (self reported)	1.06	1	0	0.0	0.00	1.0e+00	IGF2BP2
Smoking Status	1.01	2	0	0.0	0.00	1.0e+00	CTSW KIFC2
Worry (Nagel 2018)	0.96	1	0	0.0	0.00	1.0e+00	GIN1
LDL Cholesterol	0.93	1	0	0.0	0.00	1.0e+00	FNDC4
Hair Pigment	0.92	10	7	15.6	0.02	9.5e-01	AC010883.5 CDKAL1 CHMP4B CTSW E2F3 FNDC4 JAZF1 MPHOSPH9 MRAS ZCCHC24
Exposure to tobacco smoke at home	0.89	1	0	0.0	0.00	1.0e+00	RBM6

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Artery Aorta	7	0.235	2.1
GTEx	Prostate	2	0.240	2.1
GTEx	Thyroid	13	0.325	2.1
GTEx	Adipose Visceral Omentum	7	0.344	2.0
GTEx	Artery Tibial	8	0.213	2.0
GTEx	Brain Cerebellum	2	0.101	2.0
GTEx	Esophagus Muscularis	9	0.278	2.0
GTEx	Heart Atrial Appendage	3	0.190	2.0
GTEx	Lung	8	0.278	2.0
GTEx	Ovary	3	0.330	2.0
GTEx	Pituitary	3	0.269	2.0
GTEx	Skin Not Sun Exposed Suprapubic	8	0.325	2.0
GTEx	Whole Blood	3	0.151	2.0
GTEx	Adipose Subcutaneous	7	0.200	1.9
GTEx	Adrenal Gland	5	0.343	1.9
GTEx	Brain Cerebellar Hemisphere	5	0.336	1.9
GTEx	Brain Cortex	2	0.193	1.9
GTEx	Breast Mammary Tissue	6	0.304	1.9
GTEx	Breast Mammary Tissue (Male)	2	0.168	1.9
GTEx	Breast Mammary Tissue (Female)	2	0.122	1.9
GTEx	Cells EBV-transformed lymphocytes	2	0.141	1.9
GTEx	Cells Transformed fibroblasts	10	0.238	1.9
GTEx	Colon Transverse	5	0.242	1.9
GTEx	Esophagus Gastroesophageal Junction	7	0.484	1.9
GTEx	Esophagus Mucosa	10	0.301	1.9
GTEx	Heart Left Ventricle	1	0.065	1.9
GTEx	Muscle Skeletal	5	0.173	1.9
GTEx	Nerve Tibial	10	0.231	1.9
GTEx	Pancreas	3	0.184	1.9
GTEx	Skin Sun Exposed Lower leg	9	0.247	1.9
GTEx	Stomach	3	0.206	1.9
GTEx	Testis	6	0.190	1.9
METSIM	Adipose	11	0.239	1.9
CommonMind	Brain Pre-frontal Cortex	15	0.279	1.9
The Cancer Genome Atlas	Colon Adenocarcinoma	2	0.097	1.9
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.292	1.9
The Cancer Genome Atlas	Glioblastoma Multiforme	2	0.195	1.9
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	8	0.389	1.9
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.271	1.9
The Cancer Genome Atlas	Lung Adenocarcinoma	6	0.204	1.9
The Cancer Genome Atlas	Soft Tissue Sarcoma	2	0.187	1.9
The Cancer Genome Atlas	Thyroid Carcinoma	12	0.232	1.9
GTEx	Artery Coronary	3	0.253	1.8
GTEx	Brain Caudate basal ganglia	0	0.000	1.8
GTEx	Brain Frontal Cortex BA9	1	0.108	1.8
GTEx	Brain Hippocampus	0	0.000	1.8
GTEx	Brain Nucleus accumbens basal ganglia	2	0.231	1.8
GTEx	Brain Putamen basal ganglia	0	0.000	1.8
GTEx	Colon Sigmoid	4	0.273	1.8
GTEx	Spleen	2	0.142	1.8
GTEx	Vagina	3	0.472	1.8
NTR	Blood	9	0.375	1.8
ROSMAP	Brain Pre-frontal Cortex	6	0.137	1.8
YFS	Blood	12	0.260	1.8
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.181	1.8
The Cancer Genome Atlas	Breast Invasive Carcinoma	8	0.181	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.181	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	6	0.220	1.8
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	9	0.219	1.8
The Cancer Genome Atlas	Brain Lower Grade Glioma	10	0.232	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	2	0.120	1.8
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.226	1.8
The Cancer Genome Atlas	Skin Cutaneous Melanoma	3	0.561	1.8
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.156	1.8
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.391	1.8
GTEx	Small Intestine Terminal Ileum	0	0.000	1.7
GTEx	Uterus	1	0.176	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	3	0.119	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	1	0.063	1.7
The Cancer Genome Atlas	Prostate Adenocarcinoma	9	0.194	1.7
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.144	1.7
The Cancer Genome Atlas	Stomach Adenocarcinoma	1	0.059	1.7
GTEx	Brain Hypothalamus	1	0.169	1.6
GTEx	Liver	2	0.279	1.6